Cognition Therapeutics Aligns with FDA, Plans Key Trial to Start in 2027
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2026
0mins
Cognition Therapeutics announced that it received written feedback from the FDA following its recent meeting. The FDA agreed that psychosis associated with dementia with Lewy bodies could be an approvable outcome and reached alignment with the company on key aspects of a pivotal trial to support a new drug application, or NDA. The registrational program is expected to begin in mid-2027. As discussed with the FDA, Cognition expects the Phase 3 study will enroll people with DLB who experience psychosis symptoms of hallucinations and delusions. Patients receiving stable background treatment with off-label antipsychotic medications will be eligible. Following screening, participants will be randomized to receive either 100 mg of once-daily oral zervimesine or placebo for nine months. The company will work with the FDA on the analytical and statistical details for the use of the neuropsychiatric inventory as a novel primary endpoint for a pivotal trial in DLB psychosis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGTX
Wall Street analysts forecast CGTX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.070
Low
3.00
Averages
3.00
High
3.00
Current: 1.070
Low
3.00
Averages
3.00
High
3.00
About CGTX
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CGTX Shares Plunge 33% Amid Regulatory Concerns
- Trial Progress: CGTX plans to initiate a Phase 3 trial for Zervimesine targeting DLB psychosis in mid-2027, with the FDA providing favorable feedback on key aspects of the study, potentially supporting the company's future development.
- Drug Efficacy Analysis: In the Phase 2 Shimmer study, Zervimesine demonstrated significant efficacy in improving psychosis symptoms in mild-to-moderate DLB patients, with data showing an 89% reduction in the progression of hallucinations and delusions, laying a strong foundation for further research.
- Market Reaction: CGTX shares plummeted over 33% on Wednesday, marking the largest single-day drop in nearly two years, as investors expressed concerns about the company's Phase 3 program's prospects following a recent regulatory update, leading to a cautious market sentiment.
- Financial Position Analysis: As of March 31, 2026, CGTX reported approximately $31.2 million in cash and cash equivalents, which is expected to fund operations and capital expenditures through the second quarter of 2027; however, investor concerns about potential dilution remain prevalent.
See More
Cognition Therapeutics Achieves Key FDA Alignment for Zervimesine Study
- Key FDA Alignment: Cognition Therapeutics has reached a significant agreement with the U.S. FDA regarding the design of its pivotal Phase 3 study for Zervimesine targeting psychosis associated with dementia with Lewy bodies (DLB), marking a major regulatory milestone in a field lacking approved treatments.
- Trial Design Details: The planned trial will enroll DLB patients experiencing hallucinations and delusions, with randomization to either 100 mg of Zervimesine or placebo daily for nine months, utilizing the Neuropsychiatric Inventory as a primary endpoint.
- Clinical Data Foundation: The Phase 3 design builds on Phase 2 SHIMMER study results, which demonstrated that Zervimesine significantly improved psychosis symptoms compared to placebo, with a recent analysis indicating an 89% reduction in the progression of hallucinations and delusions.
- Urgent Market Need: Up to 80% of DLB patients experience psychosis, and there are currently no FDA-approved treatments available, highlighting the critical unmet medical need that Cognition Therapeutics aims to address with its research.
See More
Cognition Therapeutics Aligns with FDA on Key Trial Aspects for Dementia Drug
- Key FDA Agreement: Cognition Therapeutics has reached an agreement with the FDA confirming that the design of its registrational trial for psychosis associated with Lewy body dementia is appropriate, paving the way for future drug applications.
- Clinical Trial Timeline: The company plans to initiate its registrational program for its lead asset zervimesine in mid-2027, marking a significant step towards a new drug application and potentially enhancing its market position in dementia treatment.
- Approval Outcome Recognition: Written feedback from the FDA confirms that psychosis related to Lewy body dementia could be an approvable outcome for the pivotal study, providing strong support for Cognition Therapeutics' clinical trial and potentially accelerating the drug's market entry.
- Executive Commentary: Chief Medical Officer Anthony Caggiano stated that this agreement with the FDA represents an important milestone, indicating that the company’s trial design has received regulatory endorsement, thereby boosting investor confidence in future developments.
See More
Cognition Therapeutics Receives FDA Feedback for DLB Psychosis Clinical Trial Plans
- Positive FDA Feedback: Cognition Therapeutics received written feedback from the FDA confirming alignment on key aspects of their pivotal trial design, indicating that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome, marking a significant step towards a New Drug Application (NDA).
- Clinical Trial Design: The Phase 3 clinical trial, expected to begin in mid-2027, will enroll DLB patients experiencing hallucinations and delusions, comparing 100 mg of zervimesine against a placebo over nine months, aiming to validate its efficacy in treating these symptoms.
- Significant Efficacy: In the previous Phase 2 'SHIMMER' trial, zervimesine demonstrated an impressive 89% reduction in the progression of hallucinations and delusions among DLB patients, providing new hope for effective treatment options in this underserved population.
- Urgent Market Need: With no FDA-approved drugs for DLB and the risks associated with traditional antipsychotics, the development of zervimesine addresses a critical unmet need, potentially transforming the treatment landscape for patients suffering from debilitating psychosis.
See More
Cognition Therapeutics Receives Patent Allowance for Zervimesine
- Patent Allowance Granted: Cognition Therapeutics has received a Notice of Allowance from the USPTO for its lead drug candidate zervimesine (CT1812), which will protect this key formulation until 2045, and potentially until 2050 with a standard 5-year extension, significantly enhancing the company's market position in neurodegenerative disease treatments.
- Innovative Production Process: The patent covers not only the composition of zervimesine but also a proprietary production process that provides a more favorable pharmaceutical profile, improving its competitiveness in treating diseases like Alzheimer's and dementia with Lewy bodies.
- Clinical Trial Plans: Cognition Therapeutics plans to utilize this new form of zervimesine in upcoming registrational trials, particularly for treating psychosis in dementia with Lewy bodies, which is expected to offer new therapeutic options and fill a significant market gap.
- R&D Funding Support: The company has secured nearly $200 million in grants from the National Institutes of Health and related foundations to support its clinical research in neurodegenerative diseases, demonstrating its strong capabilities and market potential in innovative drug development.
See More
Cognition Therapeutics CEO to Present at Financial Conferences
- CEO Conference Presentation: Cognition Therapeutics' CEO Lisa Ricciardi is set to present at the Jefferies Global Healthcare Conference on June 4, 2026, where she will provide updates on the company's registration program for DLB psychosis, enhancing investor confidence in the company's future prospects.
- Webcast Availability: Ricciardi's presentations will be available via live and archived webcasts on the company's Investor Relations website, ensuring that a broad audience of investors and stakeholders can access critical information, thereby improving the company's transparency and market awareness.
- Clinical Research Progress: Cognition Therapeutics is advancing its lead candidate zervimesine (CT1812) in clinical trials, which has shown promising tolerability and efficacy signals in patients with DLB and mild-to-moderate Alzheimer's disease, potentially opening new market opportunities for the company.
- Funding Support Background: The company has secured nearly $200 million in grants from the National Institutes of Health and related foundations to support its research in neurodegenerative diseases, underscoring its leadership position and ongoing innovation capabilities in the industry.
See More
CGTX Shares Plunge 33% Amid Regulatory Concerns
- Trial Progress: CGTX plans to initiate a Phase 3 trial for Zervimesine targeting DLB psychosis in mid-2027, with the FDA providing favorable feedback on key aspects of the study, potentially supporting the company's future development.
- Drug Efficacy Analysis: In the Phase 2 Shimmer study, Zervimesine demonstrated significant efficacy in improving psychosis symptoms in mild-to-moderate DLB patients, with data showing an 89% reduction in the progression of hallucinations and delusions, laying a strong foundation for further research.
- Market Reaction: CGTX shares plummeted over 33% on Wednesday, marking the largest single-day drop in nearly two years, as investors expressed concerns about the company's Phase 3 program's prospects following a recent regulatory update, leading to a cautious market sentiment.
- Financial Position Analysis: As of March 31, 2026, CGTX reported approximately $31.2 million in cash and cash equivalents, which is expected to fund operations and capital expenditures through the second quarter of 2027; however, investor concerns about potential dilution remain prevalent.
See More
Cognition Therapeutics Achieves Key FDA Alignment for Zervimesine Study
- Key FDA Alignment: Cognition Therapeutics has reached a significant agreement with the U.S. FDA regarding the design of its pivotal Phase 3 study for Zervimesine targeting psychosis associated with dementia with Lewy bodies (DLB), marking a major regulatory milestone in a field lacking approved treatments.
- Trial Design Details: The planned trial will enroll DLB patients experiencing hallucinations and delusions, with randomization to either 100 mg of Zervimesine or placebo daily for nine months, utilizing the Neuropsychiatric Inventory as a primary endpoint.
- Clinical Data Foundation: The Phase 3 design builds on Phase 2 SHIMMER study results, which demonstrated that Zervimesine significantly improved psychosis symptoms compared to placebo, with a recent analysis indicating an 89% reduction in the progression of hallucinations and delusions.
- Urgent Market Need: Up to 80% of DLB patients experience psychosis, and there are currently no FDA-approved treatments available, highlighting the critical unmet medical need that Cognition Therapeutics aims to address with its research.
See More
Cognition Therapeutics Aligns with FDA on Key Trial Aspects for Dementia Drug
- Key FDA Agreement: Cognition Therapeutics has reached an agreement with the FDA confirming that the design of its registrational trial for psychosis associated with Lewy body dementia is appropriate, paving the way for future drug applications.
- Clinical Trial Timeline: The company plans to initiate its registrational program for its lead asset zervimesine in mid-2027, marking a significant step towards a new drug application and potentially enhancing its market position in dementia treatment.
- Approval Outcome Recognition: Written feedback from the FDA confirms that psychosis related to Lewy body dementia could be an approvable outcome for the pivotal study, providing strong support for Cognition Therapeutics' clinical trial and potentially accelerating the drug's market entry.
- Executive Commentary: Chief Medical Officer Anthony Caggiano stated that this agreement with the FDA represents an important milestone, indicating that the company’s trial design has received regulatory endorsement, thereby boosting investor confidence in future developments.
See More
Cognition Therapeutics Receives FDA Feedback for DLB Psychosis Clinical Trial Plans
- Positive FDA Feedback: Cognition Therapeutics received written feedback from the FDA confirming alignment on key aspects of their pivotal trial design, indicating that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome, marking a significant step towards a New Drug Application (NDA).
- Clinical Trial Design: The Phase 3 clinical trial, expected to begin in mid-2027, will enroll DLB patients experiencing hallucinations and delusions, comparing 100 mg of zervimesine against a placebo over nine months, aiming to validate its efficacy in treating these symptoms.
- Significant Efficacy: In the previous Phase 2 'SHIMMER' trial, zervimesine demonstrated an impressive 89% reduction in the progression of hallucinations and delusions among DLB patients, providing new hope for effective treatment options in this underserved population.
- Urgent Market Need: With no FDA-approved drugs for DLB and the risks associated with traditional antipsychotics, the development of zervimesine addresses a critical unmet need, potentially transforming the treatment landscape for patients suffering from debilitating psychosis.
See More
Cognition Therapeutics Receives Patent Allowance for Zervimesine
- Patent Allowance Granted: Cognition Therapeutics has received a Notice of Allowance from the USPTO for its lead drug candidate zervimesine (CT1812), which will protect this key formulation until 2045, and potentially until 2050 with a standard 5-year extension, significantly enhancing the company's market position in neurodegenerative disease treatments.
- Innovative Production Process: The patent covers not only the composition of zervimesine but also a proprietary production process that provides a more favorable pharmaceutical profile, improving its competitiveness in treating diseases like Alzheimer's and dementia with Lewy bodies.
- Clinical Trial Plans: Cognition Therapeutics plans to utilize this new form of zervimesine in upcoming registrational trials, particularly for treating psychosis in dementia with Lewy bodies, which is expected to offer new therapeutic options and fill a significant market gap.
- R&D Funding Support: The company has secured nearly $200 million in grants from the National Institutes of Health and related foundations to support its clinical research in neurodegenerative diseases, demonstrating its strong capabilities and market potential in innovative drug development.
See More
Cognition Therapeutics CEO to Present at Financial Conferences
- CEO Conference Presentation: Cognition Therapeutics' CEO Lisa Ricciardi is set to present at the Jefferies Global Healthcare Conference on June 4, 2026, where she will provide updates on the company's registration program for DLB psychosis, enhancing investor confidence in the company's future prospects.
- Webcast Availability: Ricciardi's presentations will be available via live and archived webcasts on the company's Investor Relations website, ensuring that a broad audience of investors and stakeholders can access critical information, thereby improving the company's transparency and market awareness.
- Clinical Research Progress: Cognition Therapeutics is advancing its lead candidate zervimesine (CT1812) in clinical trials, which has shown promising tolerability and efficacy signals in patients with DLB and mild-to-moderate Alzheimer's disease, potentially opening new market opportunities for the company.
- Funding Support Background: The company has secured nearly $200 million in grants from the National Institutes of Health and related foundations to support its research in neurodegenerative diseases, underscoring its leadership position and ongoing innovation capabilities in the industry.
See More
